Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.
EL MUNDO on MSN
When short stature hides a genetic cause: "In recent years, we have discovered many genes that regulate growth"
Many cases of idiopathic short stature in children may have a genetic cause. The first international guideline that guides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results